Biotech Investors & VC Firms in Europe
841 firms in this list, with a median first check of $500K. 192 of them lead rounds. Generated from verified public data and updated continuously.
Invus
New YorkPre-Seed–Late Stage
8 people
Infinitas Capital
Pre-Seed–Late Stage
17 people
Flow Capital
TorontoGrowth–Late Stage
1 person
Decacorn Capital
SingaporeSeed–Series B$300K – $600K
13 people
Overwater Ventures Llc
Palo AltoPre-Seed–Series A$400K – $2M
7 people
Ev3 Ventures Llc
New YorkPre-Seed–Series A$500K – $3M
2 people
SigmaBleyzer
HoustonGrowth$5.4M – $54M
13 people
ORI Capital
Hong KongPre-Seed–Late Stage
15 people
Eisai Innovation, Inc.
CambridgeSeed–Series A$5M
4 people
B-FLEXION
St. HelierSeed–Late Stage$500K
12 people
Elementum Ventures
San FranciscoPre-Seed–Seed$250K – $1.5M
4 people
Blindspot Ventures Management Co
BostonPre-Seed–Late Stage
5 people
Fab Co-Creation Studio Ventures
San FranciscoPre-Seed–Series A$250K – $1M
3 people
Taiho Ventures, LLC
Menlo ParkSeed–Series B
6 people
Esplanade Ventures
TorontoPre-Seed–Series B
11 people
Recharge Thematic Ventures Management Llc
New YorkSeed–Late Stage
8 people
Avego BioScience Capital
AlpharettaSeries A–Late Stage
2 people
Orbia Ventures
BostonSeed–Growth$1M – $6M
6 people
Level One Fund
MiamiSeed–Late Stage
5 people
2080 Ventures
Pre-Seed–Growth$100K – $500K
1 person
Nucleus Adventure Capital
New YorkPre-Seed–Series A
7 people
Sectoral Asset Management
MontrealSeries A–Late Stage
9 people
Socii Capital
San FranciscoSeries A–Series B
5 people
SBI Investment
TokyoPre-Seed–Growth$2M – $227M
1 person
Related lists
Investors & VC Firms in North America (13845)Investors & VC Firms in United States (12980)Investors & VC Firms in Europe (5528)Crypto & Web3 Investors & VC Firms (4819)Investors & VC Firms in Global (4182)SaaS Investors & VC Firms (3878)AI & Machine Learning Investors & VC Firms (3817)Fintech Investors & VC Firms (3737)Investors & VC Firms in Asia-Pacific (3575)Healthtech Investors & VC Firms (3445)
Data sourced from public filings and firms' own websites — see our methodology.















































































